换一批
换一批9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
作者：
Jeongha,Mok [1]
;
Myungsun,Lee [2]
;
Deog Kyeom,Kim [3]
;
Ju Sang,Kim [4]
;
Byung Woo,Jhun [5]
;
Kyung-Wook,Jo [6]
;
Doosoo,Jeon [7]
;
Taehoon,Lee [8]
;
Ji Yeon,Lee [9]
;
Jae Seuk,Park [10]
;
Seung Heon,Lee [11]
;
Young Ae,Kang [12]
;
Jung-Kyu,Lee [13]
;
Nakwon,Kwak [14]
;
Joong Hyun,Ahn [4]
;
Tae Sun,Shim [6]
;
Song Yee,Kim [12]
;
Seungmo,Kim [15]
;
Kyungjong,Kim [16]
;
Kwang-Hyuk,Seok [15]
;
Soyeong,Yoon [2]
;
Young Ran,Kim [2]
;
Jisu,Kim [17]
;
Dahae,Yim [17]
;
Seokyung,Hahn [18]
;
Sang Nae,Cho [2]
;
Jae-Joon,Yim [19]
;
MDR-END investigators
作者单位：
Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea.
[1]
Division of Clinical Research, International Tuberculosis Research Centre, Seoul, South Korea.
[2]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Centre, Seoul, South Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
[3]
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
[4]
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea.
[5]
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
[6]
Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea.
[7]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
[8]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Centre, Seoul, South Korea.
[9]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, Cheonan, South Korea.
[10]
Department of Pulmonology, Korea University Ansan Hospital, Ansan, South Korea.
[11]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
[12]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Centre, Seoul, South Korea.
[13]
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
[14]
Department of Laboratory Medicine, The Korean Institute of Tuberculosis, Cheongju, South Korea.
[15]
Department of R&D, The Korean Institute of Tuberculosis, Cheongju, South Korea; DNA Analysis Division, Seoul Institute, National Forensic Service, Seoul, South Korea.
[16]
Medical Research Collaborating Centre, Seoul National University Hospital, Seoul, South Korea.
[17]
Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, South Korea; Medical Research Collaborating Centre, Seoul National University Hospital, Seoul, South Korea.
[18]
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: yimjj@snu.ac.kr.
[19]
主题词
男(雄)性(Male);女(雌)性(Female);人类(Humans);吡嗪酰胺(Pyrazinamide);荧光喹诺酮类(Fluoroquinolones);药物疗法, 联合(Drug Therapy, Combination);结核, 抗多种药物性(Tuberculosis, Multidrug-Resistant);抗结核药(Antitubercular Agents);治疗结果(Treatment Outcome)
DOI
10.1016/S0140-6736(22)01883-9
PMID
36522208
发布时间
2022-12-22
- 浏览0
Lancet (London, England)
Lancet (London, England)
1522-1530页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
